Abstract
The present invention relates to the use of an improved curcuminoids composition for reducing IPS levels in blood, reducing endotoxemia, protecting the integrity of the intestinal barrier, treating, decreasing and/or preventing leaky gut syndrome, reducing intestinal lipids absorption, reducing ApoB48 levels in blood and/or for in treating, decreasing and/or preventing dyslipidemia in a subject.
Original language | English |
---|---|
Patent number | WO2024041724 |
Priority date | 22/08/22 |
Publication status | Published - 29 Feb 2024 |